SOURCE: CDEX Inc.

September 20, 2007 08:00 ET

Law Enforcement Testing of the CDEX "Meth Scanner™" Demonstrates Detection of Trace Quantities of Methamphetamine

CDEX CEO Malcolm Philips Will Appear on MN1 (http://www.mn1.com) at 1:00PM (CT) on Thursday, September 20, 2007

TUCSON, AZ--(Marketwire - September 20, 2007) - CDEX Inc. (OTCBB: CEXI) announces the results of testing by the Greenlee County Sheriff's Department of the CDEX ID2 ("Meth Scanner™"). The Greenlee County Sheriff's Department tested the ability of the Meth Scanner to detect trace quantities of methamphetamine on various surfaces including clothing, baby toys and hard surfaces. Portions of the target surfaces were contaminated with trace quantities (less than the eye can see) of methamphetamine supplied by the Sheriff's Department. Contaminated and uncontaminated surfaces were scanned by members of the Sheriff's Department and the results tabulated. The Meth Scanner detected the trace quantities of methamphetamine 100% of the time with no false positives. (The report is contained on the CDEX web site at www.cdex-inc.com.)

The CDEX ID2 ('Meth Scanner") is a hand held, battery operated device that detects trace quantities of methamphetamine on surfaces, including clothing and skin, in a continuous scan mode from standoff distances of 2-8 inches. The Meth Scanner requires no operator interpretation of results and detects methamphetamine in a continuous scan mode without damaging the substance under investigation. The Meth Scanner is in its second round of beta testing with Law Enforcement Agencies.

"The Greenlee County Sheriff's Department has been an outstanding beta partner testing the Meth Scanner in the field and the lab," said Tim Shriver, Jr., CDEX Project Manager for the Meth Scanner. "They have given us good feedback on use of the ID2 resulting in improvements in a number of areas. We are talking with potential distribution partners for the Meth Scanner and expect to begin marketing in CY 2007."

About CDEX Inc.

CDEX Inc. is a technology development company with a current focus on developing and marketing products using chemical detection and validation technologies. At present, CDEX is applying its resources in two distinct areas: (I) identification of substances of concern (e.g., explosives and illegal drugs for homeland security); and (II) validation of substances for anti-counterfeiting, brand protection and quality assurance (e.g., validation of prescription medication and detection of counterfeit or sub-par products for brand protection). ValiMed™ is a CDEX solution for the healthcare market. Corporate headquarters and research and development facilities for CDEX are located in Tucson, Arizona. For more information, visit www.cdex-inc.com and www.valimed.com or contact Malcolm Philips (mphilips@cdex-inc.com) or Stuart Poteet (spoteet@cdex-inc.com) at 520.745.5172 X 210 or 202.

Any statements made in this press release which contain information that is not historical are essentially forward-looking, as that term is defined in the federal securities laws. Many forward-looking statements can be identified by the use of words such as "expects," "plans," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning. These statements are subject to risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, the ability of the Company to raise capital to finance the development of its products, the effectiveness, profitability and marketability of those products, the ability of the Company to protect its proprietary information, the establishment of an efficient corporate operating structure as the Company grows and, other risks detailed from time-to-time in filings with the Securities and Exchange Commission. There is no obligation to publicly update any forward-looking statements.

Contact Information